Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Introduction
  • Results
  • Discussion
  • Methods
  • Author contributions
  • Supplemental material
  • Acknowledgments
  • Footnotes
  • References
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research ArticleNeuroscience Free access | 10.1172/JCI136956

Neddylation stabilizes Nav1.1 to maintain interneuron excitability and prevent seizures in murine epilepsy models

Wenbing Chen,1 Bin Luo,1 Nannan Gao,1 Haiwen Li,1 Hongsheng Wang,1 Lei Li,1,2 Wanpeng Cui,1 Lei Zhang,1 Dong Sun,1 Fang Liu,3 Zhaoqi Dong,1 Xiao Ren,1 Hongsheng Zhang,1 Huabo Su,3 Wen-Cheng Xiong,1,4 and Lin Mei1,4

1Department of Neurosciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.

2School of Life Science and Technology, ShanghaiTech University, Shanghai, China.

3Medical College of Georgia, Augusta University, Augusta, Georgia, USA.

4Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.

Address correspondence to: Lin Mei, Department of Neurosciences, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio, USA. Phone: 216.368.4928; Email: lin.mei@case.edu.

Authorship note: W Chen, BL, and NG contributed equally to this work.

Find articles by Chen, W. in: PubMed | Google Scholar

1Department of Neurosciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.

2School of Life Science and Technology, ShanghaiTech University, Shanghai, China.

3Medical College of Georgia, Augusta University, Augusta, Georgia, USA.

4Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.

Address correspondence to: Lin Mei, Department of Neurosciences, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio, USA. Phone: 216.368.4928; Email: lin.mei@case.edu.

Authorship note: W Chen, BL, and NG contributed equally to this work.

Find articles by Luo, B. in: PubMed | Google Scholar |

1Department of Neurosciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.

2School of Life Science and Technology, ShanghaiTech University, Shanghai, China.

3Medical College of Georgia, Augusta University, Augusta, Georgia, USA.

4Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.

Address correspondence to: Lin Mei, Department of Neurosciences, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio, USA. Phone: 216.368.4928; Email: lin.mei@case.edu.

Authorship note: W Chen, BL, and NG contributed equally to this work.

Find articles by Gao, N. in: PubMed | Google Scholar

1Department of Neurosciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.

2School of Life Science and Technology, ShanghaiTech University, Shanghai, China.

3Medical College of Georgia, Augusta University, Augusta, Georgia, USA.

4Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.

Address correspondence to: Lin Mei, Department of Neurosciences, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio, USA. Phone: 216.368.4928; Email: lin.mei@case.edu.

Authorship note: W Chen, BL, and NG contributed equally to this work.

Find articles by Li, H. in: PubMed | Google Scholar |

1Department of Neurosciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.

2School of Life Science and Technology, ShanghaiTech University, Shanghai, China.

3Medical College of Georgia, Augusta University, Augusta, Georgia, USA.

4Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.

Address correspondence to: Lin Mei, Department of Neurosciences, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio, USA. Phone: 216.368.4928; Email: lin.mei@case.edu.

Authorship note: W Chen, BL, and NG contributed equally to this work.

Find articles by Wang, H. in: PubMed | Google Scholar |

1Department of Neurosciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.

2School of Life Science and Technology, ShanghaiTech University, Shanghai, China.

3Medical College of Georgia, Augusta University, Augusta, Georgia, USA.

4Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.

Address correspondence to: Lin Mei, Department of Neurosciences, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio, USA. Phone: 216.368.4928; Email: lin.mei@case.edu.

Authorship note: W Chen, BL, and NG contributed equally to this work.

Find articles by Li, L. in: PubMed | Google Scholar

1Department of Neurosciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.

2School of Life Science and Technology, ShanghaiTech University, Shanghai, China.

3Medical College of Georgia, Augusta University, Augusta, Georgia, USA.

4Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.

Address correspondence to: Lin Mei, Department of Neurosciences, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio, USA. Phone: 216.368.4928; Email: lin.mei@case.edu.

Authorship note: W Chen, BL, and NG contributed equally to this work.

Find articles by Cui, W. in: PubMed | Google Scholar

1Department of Neurosciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.

2School of Life Science and Technology, ShanghaiTech University, Shanghai, China.

3Medical College of Georgia, Augusta University, Augusta, Georgia, USA.

4Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.

Address correspondence to: Lin Mei, Department of Neurosciences, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio, USA. Phone: 216.368.4928; Email: lin.mei@case.edu.

Authorship note: W Chen, BL, and NG contributed equally to this work.

Find articles by Zhang, L. in: PubMed | Google Scholar |

1Department of Neurosciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.

2School of Life Science and Technology, ShanghaiTech University, Shanghai, China.

3Medical College of Georgia, Augusta University, Augusta, Georgia, USA.

4Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.

Address correspondence to: Lin Mei, Department of Neurosciences, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio, USA. Phone: 216.368.4928; Email: lin.mei@case.edu.

Authorship note: W Chen, BL, and NG contributed equally to this work.

Find articles by Sun, D. in: PubMed | Google Scholar

1Department of Neurosciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.

2School of Life Science and Technology, ShanghaiTech University, Shanghai, China.

3Medical College of Georgia, Augusta University, Augusta, Georgia, USA.

4Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.

Address correspondence to: Lin Mei, Department of Neurosciences, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio, USA. Phone: 216.368.4928; Email: lin.mei@case.edu.

Authorship note: W Chen, BL, and NG contributed equally to this work.

Find articles by Liu, F. in: PubMed | Google Scholar

1Department of Neurosciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.

2School of Life Science and Technology, ShanghaiTech University, Shanghai, China.

3Medical College of Georgia, Augusta University, Augusta, Georgia, USA.

4Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.

Address correspondence to: Lin Mei, Department of Neurosciences, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio, USA. Phone: 216.368.4928; Email: lin.mei@case.edu.

Authorship note: W Chen, BL, and NG contributed equally to this work.

Find articles by Dong, Z. in: PubMed | Google Scholar

1Department of Neurosciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.

2School of Life Science and Technology, ShanghaiTech University, Shanghai, China.

3Medical College of Georgia, Augusta University, Augusta, Georgia, USA.

4Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.

Address correspondence to: Lin Mei, Department of Neurosciences, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio, USA. Phone: 216.368.4928; Email: lin.mei@case.edu.

Authorship note: W Chen, BL, and NG contributed equally to this work.

Find articles by Ren, X. in: PubMed | Google Scholar

1Department of Neurosciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.

2School of Life Science and Technology, ShanghaiTech University, Shanghai, China.

3Medical College of Georgia, Augusta University, Augusta, Georgia, USA.

4Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.

Address correspondence to: Lin Mei, Department of Neurosciences, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio, USA. Phone: 216.368.4928; Email: lin.mei@case.edu.

Authorship note: W Chen, BL, and NG contributed equally to this work.

Find articles by Zhang, H. in: PubMed | Google Scholar

1Department of Neurosciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.

2School of Life Science and Technology, ShanghaiTech University, Shanghai, China.

3Medical College of Georgia, Augusta University, Augusta, Georgia, USA.

4Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.

Address correspondence to: Lin Mei, Department of Neurosciences, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio, USA. Phone: 216.368.4928; Email: lin.mei@case.edu.

Authorship note: W Chen, BL, and NG contributed equally to this work.

Find articles by Su, H. in: PubMed | Google Scholar |

1Department of Neurosciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.

2School of Life Science and Technology, ShanghaiTech University, Shanghai, China.

3Medical College of Georgia, Augusta University, Augusta, Georgia, USA.

4Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.

Address correspondence to: Lin Mei, Department of Neurosciences, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio, USA. Phone: 216.368.4928; Email: lin.mei@case.edu.

Authorship note: W Chen, BL, and NG contributed equally to this work.

Find articles by Xiong, W. in: PubMed | Google Scholar |

1Department of Neurosciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.

2School of Life Science and Technology, ShanghaiTech University, Shanghai, China.

3Medical College of Georgia, Augusta University, Augusta, Georgia, USA.

4Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.

Address correspondence to: Lin Mei, Department of Neurosciences, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio, USA. Phone: 216.368.4928; Email: lin.mei@case.edu.

Authorship note: W Chen, BL, and NG contributed equally to this work.

Find articles by Mei, L. in: PubMed | Google Scholar |

Authorship note: W Chen, BL, and NG contributed equally to this work.

Published March 2, 2021 - More info

Published in Volume 131, Issue 8 on April 15, 2021
J Clin Invest. 2021;131(8):e136956. https://doi.org/10.1172/JCI136956.
© 2021 American Society for Clinical Investigation
Published March 2, 2021 - Version history
Received: February 3, 2020; Accepted: February 23, 2021
View PDF

Related article:

Epilepsy channelopathies go neddy: stabilizing NaV1.1 channels by neddylation
Stephen C. Cannon
Stephen C. Cannon
Commentary

Epilepsy channelopathies go neddy: stabilizing NaV1.1 channels by neddylation

  • Text
  • PDF
Abstract

Loss-of-function mutations of SCN1A encoding the pore-forming α subunit of the NaV1.1 neuronal sodium channel cause a severe developmental epileptic encephalopathy, Dravet syndrome (DS). In this issue of the JCI, Chen, Luo, Gao, et al. describe a phenocopy for DS in mice deficient for posttranslational conjugation with neural precursor cell expressed, developmentally downregulated 8 (NEDD8) (neddylation), selectively engineered in inhibitory interneurons. Pursuing the possibility that this phenotype is also caused by loss of NaV1.1, Chen, Luo, Gao, and colleagues show that interneuron excitability and GABA release are impaired, NaV1.1 degradation rate is increased with a commensurate decrease of NaV1.1 protein, and NaV1.1 is a substrate for neddylation. These findings establish neddylation as a mechanism for stabilizing NaV1.1 subunits and suggest another pathomechanism for epileptic sodium channelopathy.

Authors

Stephen C. Cannon

×

Abstract

The excitability of interneurons requires Nav1.1, the α subunit of the voltage-gated sodium channel. Nav1.1 deficiency and mutations reduce interneuron excitability, a major pathological mechanism for epilepsy syndromes. However, the regulatory mechanisms of Nav1.1 expression remain unclear. Here, we provide evidence that neddylation is critical to Nav1.1 stability. Mutant mice lacking Nae1, an obligatory component of the E1 ligase for neddylation, in parvalbumin-positive interneurons (PVINs) exhibited spontaneous epileptic seizures and premature death. Electrophysiological studies indicate that Nae1 deletion reduced PVIN excitability and GABA release and consequently increased the network excitability of pyramidal neurons (PyNs). Further analysis revealed a reduction in sodium-current density, not a change in channel property, in mutant PVINs and decreased Nav1.1 protein levels. These results suggest that insufficient neddylation in PVINs reduces Nav1.1 stability and thus the excitability of PVINs; the ensuing increased PyN activity causes seizures in mice. Consistently, Nav1.1 was found reduced by proteomic analysis that revealed abnormality in synapses and metabolic pathways. Our findings describe a role of neddylation in maintaining Nav1.1 stability for PVIN excitability and reveal what we believe is a new mechanism in the pathogenesis of epilepsy.

Graphical Abstract
graphical abstract
Introduction

In the CNS, proper neural activities between excitatory pyramidal neurons (PyNs) and inhibitory interneurons (INs) are critical to brain function. In particular, parvalbumin-positive (PV+) interneurons (PVINs) are a major source of inhibitory signal in maintaining excitation-inhibition (E-I) balance. PVINs fire at high frequency and, via feedback and feedforward inhibitions, are necessary for the generation of local circuit oscillations and connectivities or synchronization between brain regions (1–6).The excitability of PVINs requires Nav1.1, the α subunit of voltage-gated sodium channel that is specifically expressed in PVINs (7–13). Nav1.1 deficiency reduces PVIN excitability, increases the threshold of action potential (AP), and decreases AP amplitudes (7, 8, 12, 14–16). On the other hand, PVINs are controlled by a heterogeneous group of voltage-gated potassium channels (such as Kv3.1, Kv3.2, Kv3.3, and KCNQ2/3) whose mutations also change their excitability (17–19). In accordance with this, mutations in Nav1.1 channels have been identified in patients with mild as well as severe forms of epilepsy, including severe myoclonic epilepsy of infancy (SMEI or Dravet syndrome) as well as those with generalized epilepsy with febrile seizures plus (GEFS+) (20–22). Studies of mouse models with Nav1.1 mutations or deletions suggest that epilepsy may be caused by impaired firing of GABAergic INs (7, 12, 16, 23–25). A unified loss-of-function hypothesis posits that mild impairment of Nav1.1 functions causes febrile seizures, intermediate loss-of-function gives rise to GEFS+ epilepsy, and severe impairment causes the intractable seizures and comorbidities of SMEI (26). However, in contrast with the impact of Nav1.1 mutations on channel properties, less is known about mechanisms in regulating Nav1.1’s stability or expression. Nevertheless, mutations could be pathogenic via reducing surface expression caused by aberrant folding, trafficking, or degradation (27, 28).

Neddylation is a chemical reaction in which the ubiquitin-like protein neural precursor cell expressed, developmentally downregulated 8 (Nedd8) is conjugated to the lysine of substrate proteins by its C-terminal glycine (29). Like ubiquitination, neddylation requires Nedd8-specific E1, a heterodimer of NAE1 (also known as APP-BP1) and UBA3, which together activate NEDD8 in an ATP-dependent manner, UBC12 (a Nedd8 E2 enzyme), and substrate-specific E3 ligases. Neddylated proteins could be deneddylated by NEDD8-specific proteases, such as the COP9 signalosome (CSN) and NEDP1 (also known as SENP8; ref. 30). Nedd8 is evolutionarily highly conserved and ubiquitously expressed in many cell types (31, 32). Neddylation regulates a variety of cellular processes, including gene transcription, cell division and differentiation, ribosome biogenesis, apoptosis, and proteolysis (33–35). However, the function of neddylation in the brain is less clear, although it has been recently implicated in the development of the neuromuscular junction and excitatory synapses onto PyNs (36, 37).

In this study, we determined whether the development and function of INs is regulated by neddylation. To this end, we mutated NAE1, an obligatory subunit of the only identified Nedd8 E1 enzyme, specifically in PVINs. Unexpectedly, mutant (mt) mice displayed spontaneous epileptic seizures, impaired inhibitory synaptic transmission, and decreased excitability. Yet morphological studies suggest that the mutation had no apparent effect on the number of PVINs in the cortex and hippocampus. Remarkably, the release of GABA, but not glutamate, was reduced in mt mice, which was associated with reduced excitability of PVINs, suggesting that neddylation is critical to controlling the excitability of INs. Further molecular mechanistic studies identified Nav1.1 as a target of Nae1 mutation, which becomes unstable in the absence of neddylation. This notion was supported by proteomic analysis, which also reveals abnormality in synapses and metabolic pathways. Finally, elevated PVIN excitability was attenuated by rescue expression of Nav1.1 in Nae1 mt mice. Together, the results demonstrate a role of neddylation for Nav1.1 stability and GABAergic transmission.

Results

Ataxia and spontaneous epileptic seizures in PV-specific Nae1-deficient mice. To investigate the potential role of neddylation in PVINs, we crossed floxed Nae1 mice (38) with PV-Cre mice in which Cre expression was under the control of the PV promoter (ref. 39 and Figure 1A). NAE1 expression in the brain of PV-Nae1–/– mice was characterized. Quantitative real-time PCR (RT-PCR) and Western blot (WB) analyses of hippocampal tissues showed a trend of reduction of NAE1 mRNA and protein between PV-Nae1–/– and PV-Cre mice, but the reduction was statistically insignificant (Supplemental Figure 1, A–C; supplemental material available online with this article; https://doi.org/10.1172/JCI136956DS1). This was not unexpected because NAE1 is expressed in many types of cells in the brain, including PyN and astrocytes. In accordance with this, immunostaining indicated that NAE1 was reduced in PVINs of hippocampal sections, while no change was observed in PV-negative cells (Figure 1B), suggesting that NAE1 was specifically reduced in PVINs. To test this notion further, cortical neurons were cultured from PV-Cre::Ai9 mice (referred to as PV-Ai9), where tdTomato was specifically expressed in PVINs (40). NAE1 was detectable in PV-positive cells from PV-Ai9 mice, but not those from PV-Nae1–/–-Ai9 mice. NAE1 was also detectable in PV-negative cells, but at similar levels between the 2 genotypes (Supplemental Figure 1, D and E). Together, these results demonstrate that NAE1 was specifically ablated in PVINs in PV-Nae1–/– mice. PV-Nae1–/– mice showed no difference in brain size and gross cortical morphology, including the thickness and the number of neurons in the somatosensory cortex, compared with PV-Cre mice (Supplemental Figure 2).

Spontaneous seizures and premature death in Nae1-deficient mice.Figure 1

Spontaneous seizures and premature death in Nae1-deficient mice. (A) Schematic diagram of breeding strategy to generate PV-Nae1–/– and PV-Cre mice. (B) Specific ablation of Nae1 in PVINs. Hippocampus sections of PV-Cre (top) and PV-Nae1–/– (bottom) mice were stained with anti-Nae1 (green) and anti-PV (red) antibodies. Nuclei are shown in blue (DAPI staining). Arrows show PV-positive cells, and arrowheads show PV-negative cells. Scale bar: 50 μm. n = 3 experiments. (C) Representative EEG traces of freely moving PV-Cre and PV-Nae1–/– mice. Scale bar: 20 s, 2 mV. (D) Quantitative analysis of seizure numbers within 8 hours. n = 8 mice for each genotype. PV-Cre (0 ± 0 seizure numbers) vs. PV-Nae1–/– (2 ± 0.46 seizure numbers). P < 0.001. (E) Survival curves of PV-Cre (n = 28) and PV-Nae1–/– (n = 26) mice. (F–J) No change in PVIN number in hippocampus of PV-Nae1–/– mice. (F) Fluorescence images showing the PVINs in the hippocampus. Scale bar: 500 μm. (G) Schematic representation of coronal sections of the hippocampus. Numbers indicate distance from bregma. (H–J) Quantification of PVINs in CA1, CA2/3, and DG regions of the 3 coronal sections. n = 7 slices, 3 mice for each genotype. Slices were stained with anti-NeuN (red) and PV (green) antibodies; nuclei are shown in blue (DAPI staining). Data are represented as mean ± SEM. ***P < 0.001, unpaired 2-tailed Student’s t test.

PV-Nae1–/– mice exhibited signs of ataxia and seizure in a development-dependent manner. Beginning on P18, they showed limb tremors and imbalanced or uncoordinated walking or stumbling (Supplemental Video 1). None of these phenotypes were observed in control PV-Cre mice at any ages. We assessed ataxia phenotypes by behavioral tests. As shown in Supplemental Figure 3, A–C, in the balance beam test, the latency and distance walked prior to falling from the beam were reduced in PV-Nae1–/– mice compared with that in control PV-Cre mice (latency: 14.5 ± 6.9 s in mt versus 60.0 ± 0.0 s in control, P < 0.0001; distance walked: 9.1 ± 1.6 cm in mt versus 122.8 ± 13.2 cm in control, P < 0.0001; n = 8 mice per genotype). To assess the motor reflex, mice were tail suspended above a wire lid of a cage, as described previously (ref. 41, see also Methods). Control mice would outstretch forelimbs to reach downward for the cage lid (Supplemental Figure 3D). However, PV-Nae1–/– mice displayed a curved body posture and seemingly were unable to reach for the lid. The reflex response time was reduced in mt mice compared with control mice (Supplemental Figure 3E; 29.7% ± 4.09% in mt versus 96.8% ± 1.33% in control, P < 0.0001; n = 8 mice per genotype). These results indicate that the Nae1 mutation in PVINs causes ataxia-like phenotypes in mice. PV-Nae1–/– mice began to display epileptic seizures around P30 (Supplemental Video 2), which were associated with epileptiform discharges by EEG recording (Figure 1C). At P40, 1 seizure onset was observed every 4 hours (Figure 1D), and the frequency and severity of seizures were increased with age. At P47, PV-Nae1–/– mice began to die, which resulted from a general seizure or sudden unexpected death in epilepsy (Figure 1E). These results demonstrate a critical role of NAE1 of PVIN in regulating brain activity.

A necessary role of Nae1 for PVIN excitability. To investigate the underlying mechanisms, we quantified the number of PVINs in PV-Nae1–/– mice in the hippocampus, but failed to detect any difference between the mt and control mice (Figure 1, F–J). Similar results were observed in the medial prefrontal cortex (mPFC) and amygdala (Supplemental Figure 4). Next, we recorded spontaneous excitatory postsynaptic currents (sEPSCs) in CA1 PyNs in whole-cell patch configurations without blocking glutamatergic and GABAergic transmission. Interestingly, the frequency of sEPSC in CA1 PyNs was increased without altered amplitude (Figure 2, A–C; sEPSC frequency, 2.64 ± 0.30 Hz in mt versus 1.66 ± 0.32 Hz in control, P < 0.05; sEPSC amplitude 19.17 ± 0.99 pA in mt versus 18.60 ± 0.65 pA in control, P = 0.6372; n = 9 neurons from 3 mice per genotype), indicating increased PyN activity in mt mice. To determine whether this was due to altered function of PVINs or PyNs, we next measured spontaneous inhibitory postsynaptic currents (sIPSCs) of CA1 PyNs in the presence of 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) and DL-2-amino-5-phosphonopentanoic acid (DL-AP5) (antagonists of AMPA receptors and NMDA receptors, respectively) to block glutamatergic transmission. As shown in Figure 2, D and E, sIPSC frequency was reduced in PV-Nae1–/– mice compared with that in PV-Cre mice (sIPSC frequency, 6.92 ± 0.93 Hz in mt versus 11.39 ± 1.16 Hz in control, P < 0.01; n = 12 neurons from 4 control mice; n = 11 neurons from 4 mt mice). However, Nae1 mutation had little effect on sIPSC amplitudes (Figure 2F; sIPSC amplitude, 43.4 ± 4.36 pA in mt versus 39.9 ± 2.70 pA in control, P = 0.503). These results suggest that the Nae1 mutation may decrease GABAergic transmission from PVINs onto PyNs in the hippocampus. Next, we recorded sEPSCs when GABAergic transmission was blocked by bicuculline (an antagonist of GABAA receptors), but failed to detect any difference in sEPSC frequency or amplitudes (Figure 2, G–I; sEPSC frequency, 1.49 ± 0.18 Hz in mt versus 1.48 ± 0.16 Hz in control, P = 0.9501; sEPSC amplitude, 17.7 ± 1.00 pA in mt versus 16.5 ± 0.71 pA in control, P = 0.3407; n = 11 neurons from 4 mice per genotype). These observations indicate that the increase in sEPSC is likely caused by reduced GABA release from PVINs.

Reduced GABAergic neurotransmission in PV-Nae1–/– hippocampus.Figure 2

Reduced GABAergic neurotransmission in PV-Nae1–/– hippocampus. (A) Representative sEPSC traces of CA1 PyNs without blocking GABAergic and glutamatergic transmission. Left, schematic diagram of recording. Scale bar: 3 s, 40 pA. (B) Increased sEPSC frequency. n = 9 neurons, 3 mice for each genotype. (C) No difference in sEPSC amplitudes. (D) Representative sIPSC traces of CA1 PyNs with blocking glutamatergic transmission (right). Left, schematic diagram of recording. Scale bar: 1 s, 50 pA. (E) Decreased sIPSC frequency. n = 11–12 neurons, 4 mice for each genotype. (F) No difference in sIPSC amplitudes. (G) Representative sEPSC traces of CA1 PyNs with blocking GABAergic transmission (right). Left, schematic diagram of recording. Scale bar: 3 s, 40 pA. (H) No difference in sEPSC frequency. n = 11 neurons, 4 mice for each genotype. (I) No difference in sEPSC amplitudes. Data are represented as mean ± SEM. *P < 0.05; **P < 0.01, unpaired 2-tailed Student’s t test.

To investigate the mechanisms of reduced GABA release in PV-Nae1–/– mice, we examined the intrinsic excitability of CA1 PVINs by clamping in a whole-cell configuration. APs of PVINs were elicited by injecting depolarizing currents at different intensities in the presence of bicuculline, CNQX, and DL-AP5 to block both inhibitory and excitatory neurotransmission. Intriguingly, the firing frequency of PVINs in response to depolarizing currents was lower in PV-Nae1–/–-Ai9 mice compared with PV-Ai9 mice (Figure 3, A and B; gene effect, F1,196 = 34.36, P < 0.0001; interaction effect, F6,196 = 3.15, P < 0.01; 2-way ANOVA). A similar reduction in PVIN firing frequency was observed in the mPFC and amygdala of PV-Nae1–/–-Ai9 mice (Supplemental Figure 5). In contrast, there was no difference in the resting membrane potential (RMP), membrane capacitance (Cm), and input resistance (Rin) of PVINs between PV-Ai9 and PV-Nae1–/–-Ai9 mice (Figure 3, C–E). Importantly, the firing frequency of PyNs in the presence of bicuculline, CNQX, and DL-AP5 was similar between the 2 genotypes (Figure 3, F and G; gene effect, F1,168 = 0.2578, P = 0.6123; interaction effect, F6,168 = 0.158, P = 0.9872; 2-way ANOVA). Moreover, no difference was observed in passive membrane properties of PyNs (Figure 3, H–J), including RMP, Cm, and Rin of PyNs between PV-Ai9 and PV-Nae1–/–-Ai9 mice. However, in the absence of glutamatergic and GABAergic transmission blockers, PyN firing was increased in PV-Nae1–/–-Ai9 mice compared with controls (Figure 3, K and L; gene effect, F1,119 = 27.52, P < 0.0001; interaction effect, F6,119 = 2.568, P < 0.05; 2-way ANOVA). Together, these results indicate that Nae1 deletion in PVINs reduces the intrinsic excitability of PVINs, but not that of PyNs. The resulting reduced GABA release subsequently led to increased PyN firing and glutamatergic transmission. The effect of Nae1 mutation on PVINs was specific because it had little effect on the excitability of cholecystokinin-positive INs (CCKINs) (Supplemental Figure 6, A–C) or the RMP and current-voltage relationship of astrocytes that may regulate neuronal activity (Supplemental Figure 6, D–H).

Impaired PVIN intrinsic excitability in PV-Nae1–deficient mice.Figure 3

Impaired PVIN intrinsic excitability in PV-Nae1–deficient mice. (A and B) Impaired PVIN intrinsic excitability of PV-Nae1–deficient mice with blocking glutamatergic and GABAergic transmissions. Schematic diagram of recording (left in A) and representative AP traces (right in A). Quantification of current injection–induced APs in PVINs (B). n = 15 neurons, 4 mice for each genotype. Scale bar: 0.2 s, 30 mV. (C–E) No difference in RMP (C), Cm (D), or Rin (E) in PVINs between the 2 groups. n = 19 neurons, 4 mice for each genotype. (F and G) No change in PyN intrinsic excitability in CA1 of PV-Nae1–deficient mice. Schematic diagram of recording (left in F) and representative AP traces (right in F). Quantification of current injection–induced APs in PyNs (G). n = 12–14 neurons, 4 mice for each genotype. Scale bar: 0.2 s, 40 mV. (H–J) No difference in RMP (H), Cm(I), or Rin (J) in CA1 PyNs between the 2 groups. n = 26 neurons, 4 mice for each genotype. (K and L) Increased PyN network excitability in CA1 of PV-Nae1–deficient mice. Schematic diagram of recording (left in K) and representative AP traces (right in K). Quantification of current injection–induced APs (L) in PyNs. n = 9–10 neurons, 3 mice for each genotype; Scale bar: 0.2 s, 40 mV. Data are represented as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001, unpaired 2-tailed Student’s t test (C, D, E, H, I, and J); 2-way ANOVA (B, G, and L).

Sodium-current deficiency to decrease PVIN excitability in PV-Nae1–/–-Ai9 mice. The excitability of PVINs is regulated by many proteins, including neural proteoglycan brevican (BCAN), ETS variant transcription factor 1 (ER81), and various ion channels. including hyperpolarization-activated cyclic nucleotide-gated potassium channel 4 (HCN4), voltage-gated potassium channels (KCNA1, KCNC1-3, KCNQ2, and KCNQ3), and the α subunits of voltage-gated sodium channel (SCN1A, SCN3A, and SCN8A, refs. 7, 8, 12, 17–19, 42–45). To investigate how Nae1 mutation regulates PVIN excitability, we analyzed the mRNA levels of these genes by quantitative RT-PCR analyses; no differences were observed between PV-Ai9 and PV-Nae1–/–-Ai9 mice, suggesting that Nae1 mutation in PVINs did not alter these proteins’ synthesis transcription (Supplemental Figure 7A).

To reveal the mechanisms underlying decreased PVIN excitability, we analyzed the APs elicited in response to individual injection of 400 pA depolarizing current ramp in tdTomato+ INs (Figure 4A). APs of these INs had a large and rapid afterhyperpolarization (AHP) phase (Figure 4B), as previously reported for PVINs (46, 47). Compared with control PVINs, rheobase (the minimal current to trigger the first AP) was increased in Nae1 mt PVINs (Figure 4C, rheobase, 193.3 ± 17.7 pA in mt versus 128.9 ± 12.0 pA in control, P < 0.01), consistent with reduced excitability in mt PVINs. To determine which channels may be altered by Nae1 mutation, we measured AP threshold (membrane potential to generate AP) and amplitude, the 2 events dependent on voltage-gated sodium channels (Nav; refs. 48–51). As shown in Figure 4D, AP thresholds were increased (less negative) in mt PVINs compared with those in controls (threshold, –40.4 ± 1.12 mV in mt versus –44.4 ± 1.15 mV in control, P < 0.05; n = 19 neurons from 4 mice per genotype). AP amplitudes were reduced in PVINs of Nae1 mt mice compared with those in control mice (Figure 4E; amplitude, 49.6 ± 1.88 mV in mt versus 56.3 ± 1.60 mV in control, P < 0.05). These results suggest a deficiency of Nav in Nae1 mt PVINs. Notice that the effects of Nae1 mutation on sodium channels were specific because the mutation had little effect on AHP amplitudes, which require Ca2+-activated voltage-dependent K+ channels (Figure 4F; 17.4 ± 0.98 mV in mt versus 16.6 ± 0.93 mV in control, P = 0.5839). Nae1 mutation had no effect on the AP half-widths (Figure 4G; 0.50 ± 0.02 ms in mt versus 0.48 ± 0.02 ms in control, P = 0.3744), suggesting voltage-gated potassium channels and calcium channels might not be affected (51–53). These results indicate that Nae1 mutation increased rheobase and thresholds to generate APs in PVINs, suggesting the deficient Nav as a potential mechanism (16).

Decreased Na current density and reduced Nav1.1 level and stability in PV-NFigure 4

Decreased Na current density and reduced Nav1.1 level and stability in PV-Nae1–deficient mice. (A and B) Schematic diagram of recording (A) and representative second AP waveform in CA1 PVINs evoked by a 400 pA ramp current injection (B). Scale bar: 2 ms, 10 mV. (C–G) Increased rheobase (C) and AP threshold (D). Decreased AP amplitude (E). No changed AHP amplitude (F) and AP half-width (G). n = 19 neurons, 4 mice for each genotype. (H) Representative traces of voltage-gated sodium currents in CA1 PVINs. Scale bar: 5 ms, 5 pA/pF. (I) Current-voltage curves. n = 9 neurons, 4 mice for each genotype. (J) Reduction of the maximum sodium-current density in PV-Nae1–/–-Ai9 mice. (K) Comparison of the voltage-dependence activation of sodium channels. Conductance was normalized to the maximal sodium conductance; lines were generated by Boltzmann fitting. Membrane potentials for half-maximal activation and slope factors were as follow: PV-Ai9, -35.10 ± 0.77 mV and 5.51 ± 0.66; PV-Nae1–/–-Ai9, –33.38 ± 0.87 mV and 5.75 ± 0.76. (L and M) Levels of Nav1.1 protein were lower in PV-Nae1–/–-Ai9 mice. (L) Representative blots for hippocampal tissues. (M) Quantification analysis of data. (N and O) Accelerated Nav1.1 degradation by neddylation inhibition. (N) tsA-201 cells were cotransfected with human Nav1.1 channel β1 and β2 subunits, treated with DMSO, MLN4924, or MG132. (O) Quantification analysis of data. n = 4 experiments. (P) Increased ubiquitinated Nav1.1 in PV-Nae1–/–-Ai9 mice. Cerebellar lysates were subjected to immunoprecipitation with anti-Nav1.1 antibody and immunoblotting with anti-UB (K48) antibody. n = 3 experiments. Data are represented as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001, unpaired 2-tailed Student’s t test (C, D, E, F, G, J, and M); 2-way ANOVA (O).

To further test this idea, we analyzed somatic Na+ currents in CA1 PVINs by using a prepulse protocol (ref. 54 and Figure 4H). The Na+ currents could be completely abolished by tetrodotoxin, a specific blocker of sodium channels (data not shown). Voltage-clamp step recording showed that the Nav current density (normalized by cell capacitance) was reduced in PV-Nae1–/–-Ai9 mice compared with that in PV-Ai9 mice (Figure 4, I and J; max current density 62.3% ± 9.92% in mt versus 100% ± 5.89% in control, P < 0.01; n = 9 neurons from 4 mice per genotype). Nae1 mutation had little effect on voltage-gated calcium currents or hyperpolarization-activated cyclic nucleotide-gated channel currents in PVINs (Supplemental Figure 7, B–F). Notice that the voltage dependence of activation for Na+ currents was not changed (Figure 4K), suggesting that mt PVINs have normal Nav electrophysiological properties. These results suggest that Nae1 mutation reduced Nav currents without changing Nav’s properties.

A necessary role of neddylation for Nav1.1 stability. In the mammalian CNS, Nav1.1, and Nav1.6 are abundant in PVINs, whereas Nav1.2 is mainly expressed in excitatory neurons. Nav1.3 is transiently expressed in the brain during embryonic development and normally absent in the adult (7, 11, 55). To determine whether Nav1.1 protein was reduced in PVINs of PV-Nae1–/–-Ai9 mice, we did WB analysis. As shown in Figure 4, L and M, Nav1.1, but not Nav1.6 and Atp1a1 (Na+/K+-ATPase α 1 subunit), were reduced in the hippocampus of PV-Nae1–/–-Ai9 mice. Nav1.1 reduction was also observed in cerebral cortex and cerebellum (Supplemental Figure 8), brain regions where PVINs are abundant. These results support the idea that Nav1.1 reduction may be a potential mechanism for decreased excitability of PVINs. This notion was supported by increased AP failure rate in PVINs of PV-Nae1–/–-Ai9 mice compared with PV-Ai9 mice (Supplemental Figure 9). These electrophysiologic deficits, as well as ataxia and seizure phenotypes (Figure 1 and Supplemental Figure 3), were similar to those of Nav1.1 mt mice (7, 8, 12, 16, 41). Together, these results suggest Nav1.1 deficiency as a pathology mechanism.

Next, we investigated the molecular mechanisms underlying Nav1.1 protein reduction in PV-Nae1–/–-Ai9 mice. As shown in Supplemental Figure 6A, Nav1.1 mRNA levels were similar between the genotypes. Because neddylation is known to regulate protein stability (56–58), we wondered whether Nav1.1 stability requires neddylation. To this end, hNav1.1 and 2 β subunits were transfected into human tsA-201 cells, SV40-transformed HEK293 cell that are able to express ion channels on the membrane (59). Forty-eight hours after transfection, cells were incubated with 50 μM cycloheximide (CHX) to inhibit protein synthesis and with MLN-4924, a potent and selective inhibitor of NAE (60, 61). Interestingly, Nav1.1 degradation was increased in MLN-4928–treated cells compared with nontreated cells (Figure 4, N and O), suggesting a critical role of neddylation for Nav1.1 stability. In accordance with this, K48-linked ubiquitination was increased in PV-Nae1–/–-Ai9 mice compared with PV-Ai9 mice (Figure 4P). These results suggest that neddylation may be critical to the stability of Nav1.1.

Neddylation-dependent surface expression of Nav1.1. To determine whether Nav1.1 is subjected to modification by neddylation, we transfected tsA-201 cells with Nav1.1-Myc together with HA-Nedd8. Nav1.1 was immunoprecipitated by anti-Myc antibody and probed with anti-HA antibody. Interestingly, HA signal was detected in precipitated Nav1.1; importantly, the signal was reduced in cells that were incubated with the NAE inhibitor MLN-4924 (Figure 5A). These results suggest that the channel may be neddylated in tsA-201 cells. To determine whether Nav1.1 neddylation occurs in vivo, Nav1.1 was precipitated with anti-Nav1.1 antibody from cerebellar homogenates (where PV+ cells are abundant) and probed with anti-Nedd8 antibody, as previously described (36, 62). Neddylated Nav1.1 was reduced in PV-Nae1–deficient mice compared with control mice (Figure 5B). Together, these results demonstrate that Nav1.1 is neddylated in cultured cells and in the brain.

Reduced surface expression of K1936E mt Nav1.1. (A) Inhibiting Nav1.1 neddyFigure 5

Reduced surface expression of K1936E mt Nav1.1. (A) Inhibiting Nav1.1 neddylation by MLN4924. tsA-201 cells were transfected with Nav1.1-Myc and HA-Nedd8 plasmids and treated with or without MLN-4924. n = 3 experiments. (B) Decreased Nav1.1 neddylation in PV-Nae1–/–-Ai9 mice. Neddylated Nav1.1 precipitated with anti-Nav1.1 antibody and probed with anti-NEDD8 antibody. n = 3 experiments. (C) Accelerated degradation of K1936E. tsA-201 cells were cotransfected with Nav1.1-WT, K245N or K1936E with β1 and β2 subunits, treated with CHX for indicated times, and subjected to immunoblotting. n = 3 experiments. (D) Quantification analysis of data in C. (E–G) Reduced total and surface K1936E Nav1.1 in tsA-201 cells. Representative blots for tsA-201 cells (E), quantitative data of total (F) and surface (G) levels. n = 3 experiments. (H and I) Reduced neddylation at K1936E. (H) Nav1.1-WT, K245N, and K1936E were transiently transfected in tsA-201 cells together with HA-Nedd8. (I) Quantification analysis of data. n = 3 experiments. Data are represented as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001, 1-way ANOVA (F, G, and I); 2-way ANOVA (D).

To further investigate how neddylation regulates Nav1.1, we sought to identify the lysine residues in Nav1.1 that may be subjected to neddylation. We screened for potential pathogenic lysine mutations in databases of epilepsy patients and the ClinVar in the US National Library of Medicine. Sixteen lysine missense mutations were reported in patients with epilepsy (63–69); in particular, K1936E (where lysine1936 was mutated to glutamic acid) was identified in a screen of 70 genes in 8565 patients, including 8354 epileptic patients (68) (see also Human SCN1A gene database; http://scn1a.caae.org.cn/index.php). Because K1936 is localized in the cytoplasmic region of Nav1.1, we determined whether its mutation alters the stability of the Nav1.1 protein. WT-Nav1.1 or K1936E, along with 2 β subunits, was transfected into tsA-201 cells, and their stability was studied in the presence of CHX. Compared with WT-Nav1.1, K1936E was degraded faster (Figure 5, C and D). As a control, the stability was not changed for K245N, another lysine mutation also located in the cytoplasmic domain. In agreement with this, surface and total levels of K1936E, but not K245N, were reduced (Figure 5, E–G). Concomitantly, Nav1.1 neddylation was reduced in cells expressing K1936E, but not K245N, indicating that Lys1936 is a primary neddylation site (Figure 5, H and I). These results suggest that neddylation at Lys1936 is important in maintaining the stability of Nav1.1 and that K1936E mt is less stable, identifying a potential pathological mechanism of this mutation.

To investigate whether the functional properties of Nav1.1 channels were changed by these mutations, tsA-201 cells were transfected with WT-Nav1.1, K245N, or K1936E, together with β1 and β2 subunits and GFP (70), and were recorded by patch clamp in whole-cell configuration. The current-voltage curves showed that the current density was reduced in cells expressing K1936E, but not K245N, compared with WT (Figure 6, A and B). Notice that the coprecipitation of mt Nav1.1 and β1 or β2 subunits was comparable to that of WT-Nav1.1, suggesting that the K1936E mutation had no impact on Nav1.1 interaction with β1 or β2 subunits (Supplemental Figure 10). Next, we characterized the kinetics of the sodium-channel activation and inactivation. As shown in Figure 6, C and D, the curves of activation and inactivation were similar between WT-Nav1.1 and K1936E, suggesting that the mutation did not change the voltage-dependent activation and inactivation of sodium currents, respectively. In addition, K245N showed a depolarizing shift of steady-state fast inactivation. Together, these results demonstrate that the K1936E mutation reduces Nav1.1 levels without altering the channel property.

Reduced Nav current density by the K1936E mutation.Figure 6

Reduced Nav current density by the K1936E mutation. (A) Representative whole-cell sodium currents. tsA-201 cells were injected with depolarizing steps from –80 to +50 mV, with a holding potential of –120 mV. Scale bar: 2 ms, 50 pA/pF. (B) Current-voltage relationships. Whole-cell sodium currents were normalized to cell capacitance. n = 10–11 cells for each group. Sodium-current density is significantly decreased in K1936E group compared with WT group. (C) Comparison of the voltage-dependence activation of sodium channels. Conductance was normalized to the maximal sodium conductance between –80 and +20 mV; lines represent mean Boltzmann fits. n = 10–11 cells for each group. The membrane potentials for half-maximal activation and slope factors were as follows: WT, –29.3 ± 0.98 mV and 8.8 ± 0.9; K245N, –29.0 ± 1.05 mV and 9.3 ± 0.97; K1936E, –28.3 ± 1.04 mV and 9.0 ± 0.95. (D) Depolarizing shift (+6.8 mV) of steady-state fast inactivation of Nav1.1 with K245N mutation. Currents were normalized to the peak current amplitude; lines represent mean Boltzmann fits. n = 10–11 cells for each group. The membrane potentials for half-maximal inactivation and slope factors were as follows: WT, –52.7 ± 0.60 mV and 10.1 ± 0.53; K245N, –45.9 ± 0.66 mV and 10.5 ± 0.59; K1936E, –54.1 ± 0.72 mV and 10.8 ± 0.64. Data are represented as mean ± SEM.

Altered synaptic functions revealed by proteomic analysis. Sodium-channel levels and function are regulated by a variety of proteins or pathways. For example, increased intracellular calcium concentrations reduced sodium-current density (71). Sodium-channel surface expression and stability require auxiliary β subunits, such as SCN1B and SCN2B (72, 73). Fibroblast growth factor 14 (FGF14) interacts with and inhibits sodium channels (74, 75), whereas loss of FGF14 reduced Nav1.6 expression (76). Finally, neural precursor cell expressed, developmentally downregulated 4 like (NEDD4L), a ubiquitin E3 ligase, decreases the sodium-channel density at cell surface in Xenopus oocytes and heart cells (77–79). Receptor for activated C kinase 1 (RACK1) inhibits mRNA expression of Nav1.1 by binding to a silencer downstream of the SCN1A promoter (80). As shown in Supplemental Figure 11, mRNA levels of these proteins were similar between PV-Nae1–/–-Ai9 mice and PV-Ai9 mice.

To fully understand the impact of the PVIN-specific Nae1 mutation on brain function, we compared the proteomes between PV-Nae1–/–-Ai9 mice and PV-Ai9 mice (Figure 7A). Out of a total of 5167 proteins identified (Supplemental Table 1), 169 and 279 proteins were down- and upregulated, respectively, in PV-Nae1–/–-Ai9 mice compared with PV-Ai9 mice (P < 0.05; Figure 7B). As expected, NAE1 was reduced in mt brain samples (Figure 7B), in support of our hypothesis. Gene Ontology (GO) analysis of downregulated proteins implicated a variety of cellular functions (Supplemental Table 2). Interestingly, 9 of the top 20 relate to neural development, neurotransmission, and synaptic plasticity, including dendrite development, synapse organization, synaptic vesicle exocytosis, and glutamatergic transmission (Figure 7C and Supplemental Table 2), in accordance with a previous report (37). In agreement, Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis highlighted glutamatergic and dopaminergic synapses, synaptic vesicle cycle, endocannabinoid signaling, and alcoholism as well as spliceosome (Supplemental Figure 12A and Supplemental Table 3; P < 0.05). On the other hand, for upregulated proteins, GO analysis pointed to ubiquitin-regulated catabolism and protein folding and localization (Figure 7D and Supplemental Table 4), whereas KEGG analysis highlighted metabolic pathways, including propanoate, pyruvate and carbon metabolism, tRNA synthesis, phagocytosis, and ubiquitin-mediated proteolysis (Supplemental Figure 12B and Supplemental Table 5, P < 0.05). These results suggest that Nae1 is required not only for maintaining the excitability and GABA release of PVINs, but also for a plethora of cellular functions, such as RNA splicing, metabolism, protein processing and stability, and phagocytosis.

Proteomic analysis revealed reduced Nav1.1 and compromised synaptic functioFigure 7

Proteomic analysis revealed reduced Nav1.1 and compromised synaptic function and metabolic pathways in PV-Nae1–deficient mice. (A) Schematic diagram of quantitative proteomic analysis in PV-Ai9 and PV-Nae1–/–-Ai9 mice. n = 3 mice per genotype. (B) Volcano plots of differentially expressed proteins in PV-Nae1–/–-Ai9 mice over PV-Ai9 mice. Green and red dots indicate significantly down- and upregulated proteins, respectively. (C) Top 20 significantly enriched GO terms of downregulated proteins. (D) Top 20 significantly enriched GO terms of upregulated proteins. (E) Heatmap of ion channel proteins. Green, downregulated ion channels. (F) Heatmap of proteins associated with epilepsy. Green and red colors indicate down- and upregulated proteins, respectively. (G) Twelve ion channels were epilepsy-associated genes, but only Nav1.1 was significantly reduced by Nae1 mutation.

Considering compromised intrinsic excitability of PVINs in Nae1 mt mice, we wondered whether the levels of other ion channels are altered. Indeed, among the identified proteins were 53 ion channels (Figure 7E and Supplemental Table 1). However, only SCN1A and voltage-gated calcium channel auxiliary subunit γ 7 (CACNG7) were significantly changed (in fact reduced) in PV-Nae1–/–-Ai9 samples compared with control PV-Ai9 samples (Figure 7E; P < 0.05). CACNG7 is a type II transmembrane AMPA receptor regulatory protein (TARP) that regulates trafficking and channel gating of the AMPA receptors (81); however, CACNG7 mt mice were apparently normal in locomotion and excitatory transmission (81, 82), suggesting that CACNG7 reduction may not contribute to epileptic behavior in Nae1 mt mice. On the other hand, recent studies have identified 29 risk genes for epilepsy (20–22, 83–87) (Figure 7F). Intriguingly, in addition to Nav1.1/SCN1A, GABAA receptor δ subunit (GABRD, a subunit of extrasynaptic GABAA receptor) and proline-rich transmembrane protein 2 (PRRT2, a synaptic protein implicated in synaptic formation and maintenance) were also reduced (Figure 7F). However, IN-specific deletion of GABRD increased IN excitability and thus decreased PyN excitability and seizure susceptibility (88). PRRT2 mt increased intrinsic excitability of PyNs, and PRRT2 expression decreased sodium currents by Nav1.2/Nav1.6, but not Nav1.1 in HEK293 cells (89). Therefore, the reduced excitability of PVINs by Nae1 deficiency is unlikely to be due to reduced levels of GABRD or PRRT2. K+/Cl– cotransporter 2 (KCC2, encoded by Slc12a5) is a potassium-chloride cotransporter for maintaining the intracellular concentration of chloride ions (90). Its deficiency has been implicated in epileptogenesis (91, 92). As shown in Figure 7F, KCC2 levels were increased in Nae1-deficient mice compared with those in control samples, suggesting that the cause of epilepsy by Nae1 mutation could be complex and may involve KCC2 in addition to reduced levels of Nav1.1 (see Discussion).

Note that of 53 ion channels and 29 epilepsy-associated genes, 12 were identified in both groups (Figure 7G). Only Nav1.1 was reduced in PV-Nae1–/–-Ai9 compared with control samples. The results from proteomic analysis provide further evidence for a role of neddylation for Nav1.1 stability.

Restoring the excitability of Nae1 mt PVINs by expressing Nav1.1. Our hypothesis was that Nae1 deficiency reduces Nav1.1 and thus the excitability of PVINs, which causes epilepsy. To further test this, we determined whether expressing Nav1.1 in Nae1 mt PVINs ameliorates the impact of Nae1 mutation on the excitability. LSL-GFP and hNav1.1-Myc plasmids were injected into the cortex of PV-Nae1–/–-Ai9 mice (Figure 8A and ref. 93). Expression of GFP was dependent on Cre. As shown in Figure 8B, GFP and hNav1.1-Myc were detected specifically in PVINs that were labeled by tdTomato in PV-Nae1–/–-Ai9 mice. First, we determined whether hNav1.1 expression increased somatic Na+ currents in GFP+ INs. Voltage-clamp step recording showed that the Nav current density was lower in LSL-GFP–injected PV-Nae1–/–-Ai9 mice compared with LSL-GFP–injected PV-Ai9 mice; however, the Nav current density in mt mice injected with LSL-GFP and hNav1.1-Myc was increased to a level comparable to that of control mice (Figure 8, C and D, max current density 100% ± 8.92% in wt + LSL-GFP versus 64.4% ± 9.30% in mt + LSL-GFP, P < 0.05; 116.4% ± 9.66% in mt + LSL-GFP & hNav1.1-Myc versus 64.4% ± 9.30% in mt + LSL-GFP, P < 0.01; n = 8–10 neurons from 4 mice per group). Next, we analyzed the intrinsic excitability, rheobase, and single AP properties of GFP+ INs in PV-Nae1–/–-Ai9 mice. Compared with PVINs expressing LSL-GFP, neurons expressing hNav1.1-Myc generated more APs in response to injected currents, indicative of improved excitability (Figure 8, E and F; expression effect, F1,133 = 61.8, P < 0.0001; interaction effect, F6,133 = 4.71, P < 0.001; 2-way ANOVA). Nav1.1 expression also decreased AP rheobases (Figure 8G; 116.2 ± 11.2 pA in hNav1.1 versus 182.7 ± 23.1 pA in control, P < 0.05; n = 14 neurons from 5 mice per genotype) and thresholds (Figure 8H; –46.1 ± 1.53 mV in hNav1.1 versus –40.1 ± 1.29 mV in control, P < 0.01)and increased AP amplitudes (Figure 8I; 57.5 ± 1.11 mV in hNav1.1 versus 51.2 ± 1.30 mV in control, P < 0.01), but had no effect on AHP amplitudes and AP half-widths (Figure 8, J and K; AHP amplitude, 18.5 ± 1.14 mV in hNav1.1 versus 17.8 ± 1.11 mV in control, P = 0.6348; AP half-width, 0.47 ± 0.02 ms in hNav1.1 versus 0.45 ± 0.02 ms in control, P = 0.5489). These findings demonstrate that restoring hNav1.1 in neddylation-deficient PVINs was sufficient to recover the excitability, suggesting that Nav1.1 deficiency is a major mechanism of Nae1 mutation in regulating PVIN excitability. Taken together, these results indicate that Nav1.1 requires neddylation for stable expression in PVINs and thus their excitability.

Restoration of Nae1 mt PVIN excitability by expressing Nav1.1. (A) A diagraFigure 8

Restoration of Nae1 mt PVIN excitability by expressing Nav1.1. (A) A diagram of in vivo electroporation. (B) Expression of hNav1.1-Myc and GFP in PVINs. GFP (green) signaling colocalized with anti-Myc (blue). White arrows indicate PVINs. n = 3 experiments. Scale bars: 40 μm (top row); 10 μm (bottom row). (C) Current-voltage curves of sodium-current density in GFP+ neurons. n = 8–10 neurons, 5 mice for each genotype. (D) Rescue of sodium-current density by Nav1.1 expression in PV-Nae1–deficient mice. (E and F) Increased excitability of mt PVINs after expressing Nav1.1. Representative AP traces and quantification of current injection-induced APs in GFP+ IN. n = 10–11 neurons, 5 mice for each group. Scale bar: 0.2 s, 30 mV. (G–K) Rescue of AP deficits of PVINs by Nav1.1 expression in PV-Nae1 deficient mice. Decreased rheobase (G) and AP threshold (H). Increased AP amplitude (I). No effect on AHP amplitude (J) and AP half-width (K). n = 14 neurons, 5 mice for each group. Data are represented as mean ± SEM. *P < 0.05; **P < 0.01, 1-way ANOVA (D); 2-way ANOVA (F); unpaired 2-tailed Student’s t test (G, H, I, J, and K).

Discussion

In the present study, we uncovered a previously unknown mechanism for regulating the intrinsic excitability of PVINs. Loss of the obligatory subunit of neddylation E1, NAE1, reduced the intrinsic excitability of PVINs, but had little effect on their RMP, Cm, and Rin. As a result, AP thresholds were increased and amplitudes were reduced. Ensuing reduced GABA transmission and E-I imbalance resulted in spontaneous epileptic seizures. These results reveal a critical role of neddylation in regulating the excitability of INs. Further mechanistic studies identified Nav1.1 as a major target for Nae1 mutation because voltage-clamp step recording indicated that Nae1 mutation reduced the Na-current density without changing its voltage dependence. In accordance with this, WB revealed lower levels of the Nav1.1 protein in Nae1 mt mice or cells where neddylation was pharmacologically inhibited. This idea was supported by proteomic analysis, which also revealed abnormalities in synapses and metabolic pathways (see below). Finally, Nav1.1 expression restored the excitability in PVINs in Nae1 mt mice. These results demonstrate that neddylation is necessary for the stability of Nav1.1 in PVINs, revealing what we believe is a new regulatory mechanism for the excitability of INs.

Implicated in gene transcription and proteolysis, neddylation regulates cell division, differentiation, and apoptosis (33–35). Nae1 mutation in developing brain (via Emx1-Cre) impairs cortical lamination and in adult PyNs (via CaMKII-CreER) reduces spine numbers, suppresses evoked excitatory postsynaptic potential, and impairs learning and memory in mt mice (37, 94). Rapsyn, a classic adaptor protein, possesses E3 ligase activity that regulates acetylcholine receptor clustering and neuromuscular junction formation (36, 95). Here, we show that PVIN-specific mutation of Nae1 causes epilepsy and reduces the intrinsic excitability of PVINs, but has no apparent effects on that of PyNs (Figure 1C and Figure 3). No significant changes in mRNA and protein levels were observed for proteins known to regulate the excitability of PVINs, including HCN4 and voltage-gated potassium channels (Figure 7E and Supplemental Figure 7A). Among the α subunits of voltage-gated sodium channels that are critical to PVIN excitability, only Nav1.1 was reduced by WB analysis and nonbiased proteomic analysis (Figure 4M and Figure 7E). In agreement, first, AP thresholds and amplitudes, both requiring sodium channels, were increased and decreased, respectively (Figure 4, D and E). Second, the Nav current density was reduced in PV-Nae1–/–-Ai9 mice compared with control mice (Figure 4, I and J). However, the Nae1 mutation had little effect on voltage-gated calcium channels and hyperpolarization-activated cyclic nucleotide-gated channels in PVINs (Supplemental Figure 7, B–F). Third, epileptic and electrophysiological phenotypes were similar between PV-Nae1–/–-Ai9 mice and Nav1.1 heterozygous mt mice (7, 12, 16, 23, 41). Finally, in vivo expression of Nav1.1 increased the intrinsic excitability of PVINs, reduced AP thresholds, and increased AP amplitudes (Figure 8, H and I). A parsimonious interpretation of these results is that neddylation is critical to PVIN intrinsic excitability, acting by maintaining Nav1.1 stability. In support of this notion, proteomic analysis and RT-PCR failed to detect changes in proteins that regulate sodium-channel levels and functions, including auxiliary β subunits of sodium channels, FGF14, NEDD4L, and RACK1 (Supplemental Figure 11).

Mutations or loss of function in Nav1.1 causes a spectrum of epileptic syndromes such as SMEI and GEFS+. T875M and R1648H were the first missense mutations identified in patients with GEFS+ (20), and L986F was initially identified in SEMI (21). Since then, more dysfunctional mutations have been identified and have appeared to have different pathological mechanisms. For example, T875M and W1204R mutations exhibited depolarizing and hyperpolarizing shifts of channel activation, respectively (70). The R1657C mutation reduced current density, depolarizing shift of channel activation and fast recovery of slow inactivation (96). Besides the biophysical properties, mutations R1648C and G1674R may impair intracellular trafficking and reduce surface expression (28). The D1866Y mutation was reported to disrupt the interaction between Nav1.1 and the β1 subunit, altering the voltage dependence and kinetics (97). Our study shows that the K1936E mutation could reduce Nav1.1 surface expression by impairing its neddylation. In agreement with this, K48-linked ubiquitination was increased in PV-Nae1–/–-Ai9 mice compared with PV-Ai9 mice, suggesting that neddylation could increase Nav1.1’s stability by inhibiting ubiquitination. Our study thus provides what we believe is a previously unknown pathological mechanism of Nav1.1 mutations. The K245N mutation, located within the cytosolic S4-S5 linker of domain I in Nav1.1 (65), may act in a pathogenic way by decreasing fast inactivation of sodium channels without altering neddylation.

The E-I balance is not only controlled by the intrinsic excitability of PVINs, but also that of CCKINs, a major source of inhibitory signals that has been implicated in epilepsy (98). On the other hand, astrocytes could modulate the neuronal activity by altering extracellular concentrations of ATP, potassium, and glutamate and thus epileptogenesis (99–102). However, Nae1 mutation in PVINs had little effect on CCKIN intrinsic excitability and astrocytic electrophysiological properties (Supplemental Figure 5). Proteomic analysis indicates that, of the currently known 29 epilepsy-associated risk genes, in addition to Nav1.1, GABRD and PRRT2 were reduced (Figure 7F). However, IN-specific deletion GABRD increased IN excitability, as described earlier (88). PRRT2 mt mice displayed increased intrinsic excitability of PyNs (89), which was not observed in Nae1 mt mice. Moreover, PRRT2 coexpression had little effect on Nav1.1 in HEK293 cells (89). However, global GABRD knockout decreased inhibition onto granule cells and thus increased seizure susceptibility (103); PRRT2 reduction in PyNs was shown to increase the excitability of PyNs by increasing sodium-channel currents (89) and is thus likely to cause epilepsy. These suggest that the pathological mechanisms of epilepsy may be complex and may involve reduced GABRD and PRRT2 in other cells. Because Nae1 was ablated specifically in PVINs, these effects may be secondary. In addition, proteomic analysis also revealed an increase in KCC2 in PV-Nae1–/–-Ai9 mice compared with controls (Figure 7F). Low levels of KCC2 enable GABA to be excitatory in PyNs, whereas increased KCC2 in PyNs renders GABA to be inhibitory (104). These observations suggest that KCC2 increase may result from a compensatory mechanism.

Interestingly, GO and KEGG analyses of Nae1 mutation–downregulated proteins highlighted functional processes, such as dendrite development, synapse organization, synaptic vesicle exocytosis, glutamatergic transmission, dopaminergic synapses, endocannabinoid signaling, and alcoholism as well as spliceosome (Figure 7C and Supplemental Figure 12A, and Supplemental Tables 2 and 3). On the other hand, analysis of the upregulated proteins suggested changes in ubiquitin-regulated catabolism, protein folding and localization, and metabolic pathways, including propanoate, pyruvate and carbon metabolism, tRNA synthesis, phagocytosis, and ubiquitin-mediated proteolysis (Figure 7D, Supplemental Figure 12B, and Supplemental Tables 4 and 5). Determining whether these processes contribute to epileptogenesis warrants future studies. Our study identifies a regulatory mechanism of Nav1.1 stability in PVINs by neddylation and demonstrates that deficient neddylation reduces Nav1.1 levels, which reduces the excitability of PVINs and thus epilepsy. Increasing Scn1a expression could elevate the excitability of Scn1a-deficient PVINs and attenuate epileptic phenotypes in Dravet syndrome mouse models (105). Selective activators of Nav1.1 also benefit seizure (106) and other Nav1.1-associated deficits (107). Further studies are necessary to explore whether modification of neddylation represents a new therapeutic strategy for epilepsy.

Methods

Detailed methods are provided in Supplemental Methods.

Statistics. Data were analyzed with GraphPad Prism software. For analysis between 2 groups, 2-tailed unpaired Student’s t test was used. For analysis of multiple groups at single time points, 1-way ANOVA was used, followed by Tukey-Kramer post hoc multiple comparisons test. For analysis of multiple groups at multiple time points, 2-way ANOVA was used, followed by Bonferroni’s post hoc multiple comparisons test. Data were expressed as mean ± SEM. P < 0.05 was considered statistically significant.

Study approval. These studies were approved by the Institutional Animal Care and Use Committee of Augusta University and Case Western Reserve University.

Author contributions

W Chen, WCX, and LM designed research studies. W Chen, BL, NG, HL, HW, LL, W Cui, LZ, DS, FL, ZD, XR, and HZ performed experiments and analyzed data. HS provided material support and discussion. W Chen and LM wrote the manuscript.

Supplemental material

View Supplemental data

View Supplemental Table 1

View Supplemental Table 2

View Supplemental Table 3

View Supplemental Table 4

View Supplemental Table 5

View Supplemental Video 1

View Supplemental Video 2

Acknowledgments

We thank Qing K. Wang (Cleveland Clinic, Cleveland, Ohio, USA) for the generous supply of tsA-201 cells. We also thank Guanglin Xing, Zhibing Tan, Kai Zhao, and Xiangdong Sun for kind suggestions. We thank Piliang Hao and Chengqian Zhang for assistance with mass spectrometry equipment at the Biological Mass Spectrometry Core Facility, ShanghaiTech University. This work was supported by a startup grant from Case Western Reserve University.

Address correspondence to: Lin Mei, Department of Neurosciences, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio, USA. Phone: 216.368.4928; Email: lin.mei@case.edu.

Footnotes

Conflict of interest: The authors have declared that no conflict of interest exists.

Copyright: © 2021, American Society for Clinical Investigation.

Reference information: J Clin Invest. 2021;131(8):e136956.https://doi.org/10.1172/JCI136956.

See the related Commentary at Epilepsy channelopathies go neddy: stabilizing NaV1.1 channels by neddylation.

References
  1. Bartos M, et al. Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks. Nat Rev Neurosci. 2007;8(1):45–56.
    View this article via: PubMed CrossRef Google Scholar
  2. Cardin JA, et al. Driving fast-spiking cells induces gamma rhythm and controls sensory responses. Nature. 2009;459(7247):663–667.
    View this article via: PubMed CrossRef Google Scholar
  3. Sohal VS, et al. Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature. 2009;459(7247):698–702.
    View this article via: PubMed CrossRef Google Scholar
  4. Donato F, et al. Parvalbumin-expressing basket-cell network plasticity induced by experience regulates adult learning. Nature. 2013;504(7479):272–276.
    View this article via: PubMed CrossRef Google Scholar
  5. Hensch TK. Critical period plasticity in local cortical circuits. Nat Rev Neurosci. 2005;6(11):877–888.
    View this article via: PubMed CrossRef Google Scholar
  6. Hu H, et al. Interneurons. Fast-spiking, parvalbumin+ GABAergic interneurons: from cellular design to microcircuit function. Science. 2014;345(6196):1255263.
    View this article via: PubMed CrossRef Google Scholar
  7. Ogiwara I, et al. Nav1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation. J Neurosci. 2007;27(22):5903–5914.
    View this article via: PubMed CrossRef Google Scholar
  8. Rubinstein M, et al. Dissecting the phenotypes of Dravet syndrome by gene deletion. Brain. 2015;138(Pt 8):2219–2233.
    View this article via: PubMed Google Scholar
  9. Wang W, et al. The developmental changes of Na(v)1.1 and Na(v)1.2 expression in the human hippocampus and temporal lobe. Brain Res. 2011;1389:61–70.
    View this article via: PubMed CrossRef Google Scholar
  10. Tian C, et al. Molecular identity of axonal sodium channels in human cortical pyramidal cells. Front Cell Neurosci. 2014;8:297.
    View this article via: PubMed Google Scholar
  11. Lorincz A, Nusser Z. Cell-type-dependent molecular composition of the axon initial segment. J Neurosci. 2008;28(53):14329–14340.
    View this article via: PubMed CrossRef Google Scholar
  12. Frank HY, et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci. 2006;9(9):1142–1149.
    View this article via: PubMed CrossRef Google Scholar
  13. Verret L, et al. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell. 2012;149(3):708–721.
    View this article via: PubMed CrossRef Google Scholar
  14. Hedrich UB, et al. Impaired action potential initiation in GABAergic interneurons causes hyperexcitable networks in an epileptic mouse model carrying a human Na(V)1.1 mutation. J Neurosci. 2014;34(45):14874–14889.
    View this article via: PubMed CrossRef Google Scholar
  15. De Stasi AM, et al. Unaltered network activity and interneuronal firing during spontaneous cortical dynamics in vivo in a mouse model of severe myoclonic epilepsy of infancy. Cereb Cortex. 2016;26(4):1778–1794.
    View this article via: PubMed CrossRef Google Scholar
  16. Tai C, et al. Impaired excitability of somatostatin- and parvalbumin-expressing cortical interneurons in a mouse model of Dravet syndrome. Proc Natl Acad Sci U S A. 2014;111(30):E3139–E3148.
    View this article via: PubMed CrossRef Google Scholar
  17. Lau D, et al. Impaired fast-spiking, suppressed cortical inhibition, and increased susceptibility to seizures in mice lacking Kv3.2 K+ channel proteins. J Neurosci. 2000;20(24):9071–9085.
    View this article via: PubMed CrossRef Google Scholar
  18. Espinosa F, et al. Ablation of Kv3.1 and Kv3.3 potassium channels disrupts thalamocortical oscillations in vitro and in vivo. J Neurosci. 2008;28(21):5570–5581.
    View this article via: PubMed CrossRef Google Scholar
  19. Soh H, et al. Deletion of KCNQ2/3 potassium channels from PV+ interneurons leads to homeostatic potentiation of excitatory transmission. Elife. 2018;7:e38617.
    View this article via: PubMed Google Scholar
  20. Escayg A, et al. Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2. Nat Genet. 2000;24(4):343–345.
    View this article via: PubMed CrossRef Google Scholar
  21. Claes L, et al. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet. 2001;68(6):1327–1332.
    View this article via: PubMed CrossRef Google Scholar
  22. Wallace RH, et al. Neuronal sodium-channel alpha1-subunit mutations in generalized epilepsy with febrile seizures plus. Am J Hum Genet. 2001;68(4):859–865.
    View this article via: PubMed CrossRef Google Scholar
  23. Tang B, et al. A BAC transgenic mouse model reveals neuron subtype-specific effects of a generalized epilepsy with febrile seizures plus (GEFS+) mutation. Neurobiol Dis. 2009;35(1):91–102.
    View this article via: PubMed CrossRef Google Scholar
  24. Martin MS, et al. Altered function of the SCN1A voltage-gated sodium channel leads to gamma-aminobutyric acid-ergic (GABAergic) interneuron abnormalities. J Biol Chem. 2010;285(13):9823–9834.
    View this article via: PubMed CrossRef Google Scholar
  25. Cheah CS, et al. Specific deletion of NaV1.1 sodium channels in inhibitory interneurons causes seizures and premature death in a mouse model of Dravet syndrome. Proc Natl Acad Sci U S A. 2012;109(36):14646–14651.
    View this article via: PubMed CrossRef Google Scholar
  26. Catterall WA, et al. NaV1.1 channels and epilepsy. J Physiol. 2010;588(Pt 11):1849–1859.
    View this article via: PubMed Google Scholar
  27. Patino GA, et al. A functional null mutation of SCN1B in a patient with Dravet syndrome. J Neurosci. 2009;29(34):10764–10778.
    View this article via: PubMed CrossRef Google Scholar
  28. Thompson CH, et al. Nontruncating SCN1A mutations associated with severe myoclonic epilepsy of infancy impair cell surface expression. J Biol Chem. 2012;287(50):42001–42008.
    View this article via: PubMed CrossRef Google Scholar
  29. Hochstrasser M. Origin and function of ubiquitin-like proteins. Nature. 2009;458(7237):422–429.
    View this article via: PubMed CrossRef Google Scholar
  30. Gan-Erdene T, et al. Identification and characterization of DEN1, a deneddylase of the ULP family. J Biol Chem. 2003;278(31):28892–28900.
    View this article via: PubMed CrossRef Google Scholar
  31. Kamitani T, et al. Characterization of NEDD8, a developmentally down-regulated ubiquitin-like protein. J Biol Chem. 1997;272(45):28557–28562.
    View this article via: PubMed CrossRef Google Scholar
  32. Menon S, et al. COP9 signalosome subunit 8 is essential for peripheral T cell homeostasis and antigen receptor-induced entry into the cell cycle from quiescence. Nat Immunol. 2007;8(11):1236–1245.
    View this article via: PubMed CrossRef Google Scholar
  33. Rabut G, Peter M. Function and regulation of protein neddylation. ‘Protein modifications: beyond the usual suspects’ review series. EMBO Rep. 2008;9(10):969–976.
    View this article via: PubMed CrossRef Google Scholar
  34. Enchev RI, et al. Protein neddylation: beyond cullin-RING ligases. Nat Rev Mol Cell Biol. 2015;16(1):30–44.
    View this article via: PubMed Google Scholar
  35. Kandala S, et al. Neddylation and deneddylation in cardiac biology. Am J Cardiovasc Dis. 2014;4(4):140–158.
    View this article via: PubMed Google Scholar
  36. Li L, et al. Enzymatic activity of the scaffold protein rapsyn for synapse formation. Neuron. 2016;92(5):1007–1019.
    View this article via: PubMed CrossRef Google Scholar
  37. Vogl AM, et al. Neddylation inhibition impairs spine development, destabilizes synapses and deteriorates cognition. Nat Neurosci. 2015;18(2):239–251.
    View this article via: PubMed CrossRef Google Scholar
  38. Zou J, et al. Neddylation mediates ventricular chamber maturation through repression of Hippo signaling. Proc Natl Acad Sci U S A. 2018;115(17):E4101–E4110.
    View this article via: PubMed CrossRef Google Scholar
  39. Hippenmeyer S, et al. A developmental switch in the response of DRG neurons to ETS transcription factor signaling. PLoS Biol. 2005;3(5):e159.
    View this article via: PubMed CrossRef Google Scholar
  40. Madisen L, et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat Neurosci. 2010;13(1):133–140.
    View this article via: PubMed CrossRef Google Scholar
  41. Kalume F, et al. Reduced sodium current in Purkinje neurons from Nav1.1 mutant mice: implications for ataxia in severe myoclonic epilepsy in infancy. J Neurosci. 2007;27(41):11065–11074.
    View this article via: PubMed CrossRef Google Scholar
  42. Favuzzi E, et al. Activity-Dependent Gating of Parvalbumin Interneuron Function by the Perineuronal Net Protein Brevican. Neuron. 2017;95(3):639–655.
    View this article via: PubMed CrossRef Google Scholar
  43. Dehorter N, et al. Tuning of fast-spiking interneuron properties by an activity-dependent transcriptional switch. Science. 2015;349(6253):1216–1220.
    View this article via: PubMed CrossRef Google Scholar
  44. Hughes DI, et al. HCN4 subunit expression in fast-spiking interneurons of the rat spinal cord and hippocampus. Neuroscience. 2013;237:7–18.
    View this article via: PubMed CrossRef Google Scholar
  45. Li T, et al. Action potential initiation in neocortical inhibitory interneurons. PLoS Biol. 2014;12(9):e1001944.
    View this article via: PubMed CrossRef Google Scholar
  46. Rudy B, McBain CJ. Kv3 channels: voltage-gated K+ channels designed for high-frequency repetitive firing. Trends Neurosci. 2001;24(9):517–526.
    View this article via: PubMed CrossRef Google Scholar
  47. Erisir A, et al. Function of specific K(+) channels in sustained high-frequency firing of fast-spiking neocortical interneurons. J Neurophysiol. 1999;82(5):2476–2489.
    View this article via: PubMed CrossRef Google Scholar
  48. Colbert CM, Pan E. Ion channel properties underlying axonal action potential initiation in pyramidal neurons. Nat Neurosci. 2002;5(6):533–538.
    View this article via: PubMed CrossRef Google Scholar
  49. Kole MH, et al. Action potential generation requires a high sodium channel density in the axon initial segment. Nat Neurosci. 2008;11(2):178–186.
    View this article via: PubMed CrossRef Google Scholar
  50. Hodgkin AL, Huxley AF. A quantitative description of membrane current and its application to conduction and excitation in nerve. J Physiol. 1952;117(4):500–544.
    View this article via: PubMed CrossRef Google Scholar
  51. Bean BP. The action potential in mammalian central neurons. Nat Rev Neurosci. 2007;8(6):451–465.
    View this article via: PubMed CrossRef Google Scholar
  52. Aldrich RW Jr, et al. Mechanism of frequency-dependent broadening of molluscan neurone soma spikes. J Physiol. 1979;291:531–544.
    View this article via: PubMed CrossRef Google Scholar
  53. Shao LR, et al. The role of BK-type Ca2+-dependent K+ channels in spike broadening during repetitive firing in rat hippocampal pyramidal cells. J Physiol. 1999;521 Pt 1:135–146.
    View this article via: PubMed Google Scholar
  54. Milescu LS, et al. Isolation of somatic Na+ currents by selective inactivation of axonal channels with a voltage prepulse. J Neurosci. 2010;30(22):7740–7748.
    View this article via: PubMed CrossRef Google Scholar
  55. Yamagata T, et al. Nav1.2 is expressed in caudal ganglionic eminence-derived disinhibitory interneurons: mutually exclusive distributions of Nav1.1 and Nav1.2. Biochem Biophys Res Commun. 2017;491(4):1070–1076.
    View this article via: PubMed CrossRef Google Scholar
  56. Zhao Y, et al. Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapy. Antioxid Redox Signal. 2014;21(17):2383–2400.
    View this article via: PubMed CrossRef Google Scholar
  57. Xirodimas DP, et al. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell. 2004;118(1):83–97.
    View this article via: PubMed CrossRef Google Scholar
  58. Ryu JH, et al. Hypoxia-inducible factor α subunit stabilization by NEDD8 conjugation is reactive oxygen species-dependent. J Biol Chem. 2011;286(9):6963–6970.
    View this article via: PubMed CrossRef Google Scholar
  59. Tapper AR, et al. Heterologous expression of ion channels. Methods Mol Biol. 2003;217:285–294.
    View this article via: PubMed Google Scholar
  60. Brownell JE, et al. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol Cell. 2010;37(1):102–111.
    View this article via: PubMed CrossRef Google Scholar
  61. Soucy TA, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009;458(7239):732–736.
    View this article via: PubMed CrossRef Google Scholar
  62. Watson IR, et al. Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation function. J Biol Chem. 2006;281(45):34096–34103.
    View this article via: PubMed CrossRef Google Scholar
  63. Xu X, et al. Amplicon resequencing identified parental mosaicism for approximately 10% of “de novo” SCN1A mutations in children with Dravet syndrome. Hum Mutat. 2015;36(9):861–872.
    View this article via: PubMed CrossRef Google Scholar
  64. Lee HF, et al. Electroencephalographic features of patients with SCN1A-positive Dravet syndrome. Brain Dev. 2015;37(6):599–611.
    View this article via: PubMed CrossRef Google Scholar
  65. Morimoto M, et al. SCN1A mutation mosaicism in a family with severe myoclonic epilepsy in infancy. Epilepsia. 2006;47(10):1732–1736.
    View this article via: PubMed CrossRef Google Scholar
  66. Orrico A, et al. Mutational analysis of the SCN1A, SCN1B and GABRG2 genes in 150 Italian patients with idiopathic childhood epilepsies. Clin Genet. 2009;75(6):579–581.
    View this article via: PubMed CrossRef Google Scholar
  67. Abou-Khalil B, et al. Partial and generalized epilepsy with febrile seizures plus and a novel SCN1A mutation. Neurology. 2001;57(12):2265–2272.
    View this article via: PubMed CrossRef Google Scholar
  68. Lindy AS, et al. Diagnostic outcomes for genetic testing of 70 genes in 8565 patients with epilepsy and neurodevelopmental disorders. Epilepsia. 2018;59(5):1062–1071.
    View this article via: PubMed CrossRef Google Scholar
  69. Goldberg-Stern H, et al. Broad phenotypic heterogeneity due to a novel SCN1A mutation in a family with genetic epilepsy with febrile seizures plus. J Child Neurol. 2014;29(2):221–226.
    View this article via: PubMed CrossRef Google Scholar
  70. Lossin C, et al. Molecular basis of an inherited epilepsy. Neuron. 2002;34(6):877–884.
    View this article via: PubMed CrossRef Google Scholar
  71. Casini S, et al. Intracellular calcium modulation of voltage-gated sodium channels in ventricular myocytes. Cardiovasc Res. 2009;81(1):72–81.
    View this article via: PubMed CrossRef Google Scholar
  72. Isom LL, et al. Primary structure and functional expression of the beta 1 subunit of the rat brain sodium channel. Science. 1992;256(5058):839–842.
    View this article via: PubMed CrossRef Google Scholar
  73. Isom LL, et al. Structure and function of the beta 2 subunit of brain sodium channels, a transmembrane glycoprotein with a CAM motif. Cell. 1995;83(3):433–442.
    View this article via: PubMed CrossRef Google Scholar
  74. Lou JY, et al. Fibroblast growth factor 14 is an intracellular modulator of voltage-gated sodium channels. J Physiol. 2005;569(Pt 1):179–193.
    View this article via: PubMed Google Scholar
  75. Laezza F, et al. FGF14 N-terminal splice variants differentially modulate Nav1.2 and Nav1.6-encoded sodium channels. Mol Cell Neurosci. 2009;42(2):90–101.
    View this article via: PubMed CrossRef Google Scholar
  76. Shakkottai VG, et al. FGF14 regulates the intrinsic excitability of cerebellar Purkinje neurons. Neurobiol Dis. 2009;33(1):81–88.
    View this article via: PubMed CrossRef Google Scholar
  77. Rougier JS, et al. Molecular determinants of voltage-gated sodium channel regulation by the Nedd4/Nedd4-like proteins. Am J Physiol Cell Physiol. 2005;288(3):C692–C701.
    View this article via: PubMed CrossRef Google Scholar
  78. van Bemmelen MX, et al. Cardiac voltage-gated sodium channel Nav1.5 is regulated by Nedd4-2 mediated ubiquitination. Circ Res. 2004;95(3):284–291.
    View this article via: PubMed CrossRef Google Scholar
  79. Abriel H, et al. Regulation of the cardiac voltage-gated Na+ channel (H1) by the ubiquitin-protein ligase Nedd4. FEBS Lett. 2000;466(2–3):377–380.
    View this article via: PubMed Google Scholar
  80. Dong ZF, et al. Transcription of the human sodium channel SCN1A gene is repressed by a scaffolding protein RACK1. Mol Neurobiol. 2014;50(2):438–448.
    View this article via: PubMed CrossRef Google Scholar
  81. Yamazaki M, et al. TARPs gamma-2 and gamma-7 are essential for AMPA receptor expression in the cerebellum. Eur J Neurosci. 2010;31(12):2204–2220.
    View this article via: PubMed CrossRef Google Scholar
  82. Yamazaki M, et al. Relative contribution of TARPs γ-2 and γ-7 to cerebellar excitatory synaptic transmission and motor behavior. Proc Natl Acad Sci U S A. 2015;112(4):E371–E379.
    View this article via: PubMed CrossRef Google Scholar
  83. Heron SE, et al. PRRT2 mutations cause benign familial infantile epilepsy and infantile convulsions with choreoathetosis syndrome. Am J Hum Genet. 2012;90(1):152–160.
    View this article via: PubMed CrossRef Google Scholar
  84. Dibbens LM, et al. GABRD encoding a protein for extra- or peri-synaptic GABAA receptors is a susceptibility locus for generalized epilepsies. Hum Mol Genet. 2004;13(13):1315–1319.
    View this article via: PubMed CrossRef Google Scholar
  85. Stodberg T, et al. Mutations in SLC12A5 in epilepsy of infancy with migrating focal seizures. Nat Commun. 2015;6:8038.
    View this article via: PubMed Google Scholar
  86. Cossette P, et al. Mutation of GABRA1 in an autosomal dominant form of juvenile myoclonic epilepsy. Nat Genet. 2002;31(2):184–189.
    View this article via: PubMed CrossRef Google Scholar
  87. Heron SE, et al. Sodium-channel defects in benign familial neonatal-infantile seizures. Lancet. 2002;360(9336):851–852.
    View this article via: PubMed CrossRef Google Scholar
  88. Lee V, Maguire J. Impact of inhibitory constraint of interneurons on neuronal excitability. J Neurophysiol. 2013;110(11):2520–2535.
    View this article via: PubMed CrossRef Google Scholar
  89. Fruscione F, et al. PRRT2 controls neuronal excitability by negatively modulating Na+ channel 1.2/1.6 activity. Brain. 2018;141(4):1000–1016.
    View this article via: PubMed CrossRef Google Scholar
  90. Kaila K, et al. Cation-chloride cotransporters in neuronal development, plasticity and disease. Nat Rev Neurosci. 2014;15(10):637–654.
    View this article via: PubMed CrossRef Google Scholar
  91. Woo NS, et al. Hyperexcitability and epilepsy associated with disruption of the mouse neuronal-specific K-Cl cotransporter gene. Hippocampus. 2002;12(2):258–268.
    View this article via: PubMed CrossRef Google Scholar
  92. Tornberg J, et al. Behavioural phenotypes of hypomorphic KCC2-deficient mice. Eur J Neurosci. 2005;21(5):1327–1337.
    View this article via: PubMed CrossRef Google Scholar
  93. Jiao HF, et al. Transmembrane protein 108 is required for glutamatergic transmission in dentate gyrus. Proc Natl Acad Sci U S A. 2017;114(5):1177–1182.
    View this article via: PubMed CrossRef Google Scholar
  94. Zhang L, et al. Neddylation is critical to cortical development by regulating Wnt/β-catenin signaling. Proc Natl Acad Sci U S A. 2020;117(42):26448–26459.
    View this article via: PubMed CrossRef Google Scholar
  95. Xing G, et al. A mechanism in agrin signaling revealed by a prevalent Rapsyn mutation in congenital myasthenic syndrome. Elife. 2019;8:e49180.
    View this article via: PubMed Google Scholar
  96. Lossin C, et al. Epilepsy-associated dysfunction in the voltage-gated neuronal sodium channel SCN1A. J Neurosci. 2003;23(36):11289–11295.
    View this article via: PubMed CrossRef Google Scholar
  97. Spampanato J, et al. A novel epilepsy mutation in the sodium channel SCN1A identifies a cytoplasmic domain for beta subunit interaction. J Neurosci. 2004;24(44):10022–10034.
    View this article via: PubMed CrossRef Google Scholar
  98. Wyeth MS, et al. Selective reduction of cholecystokinin-positive basket cell innervation in a model of temporal lobe epilepsy. J Neurosci. 2010;30(26):8993–9006.
    View this article via: PubMed CrossRef Google Scholar
  99. Patel DC, et al. Neuron-glia interactions in the pathophysiology of epilepsy. Nat Rev Neurosci. 2019;20(5):282–297.
    View this article via: PubMed CrossRef Google Scholar
  100. Djukic B, et al. Conditional knock-out of Kir4.1 leads to glial membrane depolarization, inhibition of potassium and glutamate uptake, and enhanced short-term synaptic potentiation. J Neurosci. 2007;27(42):11354–11365.
    View this article via: PubMed CrossRef Google Scholar
  101. Steinhauser C, et al. Astrocyte dysfunction in temporal lobe epilepsy: K+ channels and gap junction coupling. Glia. 2012;60(8):1192–1202.
    View this article via: PubMed CrossRef Google Scholar
  102. Sun XD, et al. Lrp4 in astrocytes modulates glutamatergic transmission. Nat Neurosci. 2016;19(8):1010–1018.
    View this article via: PubMed CrossRef Google Scholar
  103. Spigelman I, et al. Reduced inhibition and sensitivity to neurosteroids in hippocampus of mice lacking the GABA(A) receptor delta subunit. J Neurophysiol. 2003;90(2):903–910.
    View this article via: PubMed CrossRef Google Scholar
  104. Moore YE, et al. Seizing control of KCC2: a new therapeutic target for epilepsy. Trends Neurosci. 2017;40(9):555–571.
    View this article via: PubMed CrossRef Google Scholar
  105. Colasante G, et al. dCas9-based Scn1a gene activation restores inhibitory interneuron excitability and attenuates seizures in Dravet Syndrome mice. Mol Ther. 2020;28(1):235–253.
    View this article via: PubMed CrossRef Google Scholar
  106. Richards KL, et al. Selective NaV1.1 activation rescues Dravet syndrome mice from seizures and premature death. Proc Natl Acad Sci U S A. 2018;115(34):E8077–E8085.
    View this article via: PubMed CrossRef Google Scholar
  107. Jensen HS, et al. Therapeutic potential of Na(V)1.1 activators. Trends Pharmacol Sci. 2014;35(3):113–118.
    View this article via: PubMed CrossRef Google Scholar
Version history
  • Version 1 (March 2, 2021): In-Press Preview
  • Version 2 (April 15, 2021): Electronic publication

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Introduction
  • Results
  • Discussion
  • Methods
  • Author contributions
  • Supplemental material
  • Acknowledgments
  • Footnotes
  • References
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts